178 related articles for article (PubMed ID: 33072987)
1. A Cost-Effectiveness Analysis of Newborn Screening for Severe Combined Immunodeficiency in the UK.
Bessey A; Chilcott J; Leaviss J; de la Cruz C; Wong R
Int J Neonatal Screen; 2019 Sep; 5(3):28. PubMed ID: 33072987
[TBL] [Abstract][Full Text] [Related]
2. The Cost-Effectiveness of Expanding the UK Newborn Bloodspot Screening Programme to Include Five Additional Inborn Errors of Metabolism.
Bessey A; Chilcott J; Pandor A; Paisley S
Int J Neonatal Screen; 2020 Nov; 6(4):. PubMed ID: 33233828
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of newborn screening for severe combined immunodeficiency.
Van der Ploeg CPB; Blom M; Bredius RGM; van der Burg M; Schielen PCJI; Verkerk PH; Van den Akker-van Marle ME
Eur J Pediatr; 2019 May; 178(5):721-729. PubMed ID: 30805731
[TBL] [Abstract][Full Text] [Related]
4. A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID).
Chan K; Davis J; Pai SY; Bonilla FA; Puck JM; Apkon M
Mol Genet Metab; 2011 Nov; 104(3):383-9. PubMed ID: 21810544
[TBL] [Abstract][Full Text] [Related]
5. Economic Evaluation of Newborn Screening for Severe Combined Immunodeficiency.
Shih STF; Keller E; Wiley V; Wong M; Farrar MA; Chambers GM
Int J Neonatal Screen; 2022 Jul; 8(3):. PubMed ID: 35892474
[TBL] [Abstract][Full Text] [Related]
6. Economic impact of screening for X-linked Adrenoleukodystrophy within a newborn blood spot screening programme.
Bessey A; Chilcott JB; Leaviss J; Sutton A
Orphanet J Rare Dis; 2018 Oct; 13(1):179. PubMed ID: 30309370
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington State.
Ding Y; Thompson JD; Kobrynski L; Ojodu J; Zarbalian G; Grosse SD
J Pediatr; 2016 May; 172():127-35. PubMed ID: 26876279
[TBL] [Abstract][Full Text] [Related]
8. The case for severe combined immunodeficiency (SCID) and T cell lymphopenia newborn screening: saving lives…one at a time.
Quinn J; Orange JS; Modell V; Modell F
Immunol Res; 2020 Feb; 68(1):48-53. PubMed ID: 32128663
[TBL] [Abstract][Full Text] [Related]
9. Potential costs and benefits of newborn screening for severe combined immunodeficiency.
McGhee SA; Stiehm ER; McCabe ER
J Pediatr; 2005 Nov; 147(5):603-8. PubMed ID: 16291349
[TBL] [Abstract][Full Text] [Related]
10. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
11. Systematic neonatal screening for severe combined immunodeficiency and severe T-cell lymphopenia: Analysis of cost-effectiveness based on French real field data.
Clément MC; Mahlaoui N; Mignot C; Le Bihan C; Rabetrano H; Hoang L; Neven B; Moshous D; Cavazzana M; Blanche S; Fischer A; Audrain M; Durand-Zaleski I
J Allergy Clin Immunol; 2015 Jun; 135(6):1589-93. PubMed ID: 25840725
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of insulin pumps compared with multiple daily injections both provided with structured education for adults with type 1 diabetes: a health economic analysis of the Relative Effectiveness of Pumps over Structured Education (REPOSE) randomised controlled trial.
Pollard DJ; Brennan A; Dixon S; Waugh N; Elliott J; Heller S; Lee E; Campbell M; Basarir H; White D;
BMJ Open; 2018 Apr; 8(4):e016766. PubMed ID: 29627802
[TBL] [Abstract][Full Text] [Related]
13. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
[TBL] [Abstract][Full Text] [Related]
14. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.
Batty AJ; Hansen RN; Bloudek LM; Varon SF; Hayward EJ; Pennington BW; Lipton RB; Sullivan SD
J Med Econ; 2013 Jul; 16(7):877-87. PubMed ID: 23647483
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic aspects of newborn screening for severe combined immunodeficiency: DEPISTREC study results.
Thomas C; Durand-Zaleski I; Frenkiel J; Mirallié S; Léger A; Cheillan D; Picard C; Mahlaoui N; Riche VP; Roussey M; Sébille V; Rabetrano H; Dert C; Fischer A; Audrain M
Clin Immunol; 2019 May; 202():33-39. PubMed ID: 30946917
[TBL] [Abstract][Full Text] [Related]
18. Study Design for an Evaluation of Newborn Screening for SCID in the UK.
Elliman D
Int J Neonatal Screen; 2022 Jan; 8(1):. PubMed ID: 35076461
[TBL] [Abstract][Full Text] [Related]
19. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
